Sanofi (SNY) Liabilities from Discontinued Operations (2009 - 2025)
Sanofi's (SNY) quarterly Liabilities from Discontinued Operations came in at 2263919.38 in Q2 2025, down 99.9% quarter-over-quarter from 2277176797.75 in Q4 2024.
Sanofi (SNY) Liabilities from Discontinued Operations (2009 - 2025) Analysis & Trends
Sanofi has disclosed Liabilities from Discontinued Operations across 3 years of filings, most recently posting 2263919.38 for Q2 2025.
- Liabilities from Discontinued Operations for Q2 2025 came in at 2263919.38, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was 2263919.38 (changed N/A YoY), and the FY2024 annual result was 2277176797.75, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at 2263919.38 for Q2 2025 at Sanofi, down from 2277176797.75 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 2277176797.75 in Q4 2024 to a low of 2263919.38 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Sanofi | 63.47 Mn | -6.87 Bn | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.26 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Dec 31, 2024 | 2.28 Bn |
| Dec 31, 2024 | 2.28 Bn |
| Jun 30, 2009 | 8.17 Mn |
| Jun 30, 2009 | 8.17 Mn |